DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
Recarbrio is a drug marketed by Msd Merck Co and is included in one NDA. There is one patent protecting this drug.
This drug has fifty patent family members in thirty countries.
The generic ingredient in RECARBRIO is cilastatin sodium; imipenem; relebactam . There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cilastatin sodium; imipenem; relebactam profile page.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 19, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Generic Entry Opportunity Date for RECARBRIO
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Msd Merck Co||RECARBRIO||cilastatin sodium; imipenem; relebactam||POWDER;INTRAVENOUS||212819-001||Jul 16, 2019||RX||Yes||Yes||Start Trial||Start Trial||Y||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|